EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-Type I Interferon Autoantibodies in COVID-19 and Systemic Lupus Erythematosus: A Comparative Review

Xin Rong Lim iD, Ryan Xuan Wei Teo, Rae Yi Xin Par, Bernard Pui Lam Leung iD

Antibodies · 17.06.2026 · 15 (3) · 50

DOI: 10.3390/antib15030050 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 17.06.2026. Verfasst von Xin Rong Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore 308433, Singapore. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type I interferons (IFN-I), including IFN-α, IFN-β, and IFN-ω, are central to antiviral defence and immune regulation. Autoantibodies targeting IFN-I (anti-IFN-I AAbs) have emerged as key pathogenic factors in severe coronavirus disease 2019 (COVID-19) and are detectable in systemic lupus erythematosus (SLE), a prototypic IFN-driven autoimmune disease. Here we compare the prevalence and clinical impact of anti-IFN-I autoantibodies (Aabs) in COVID-19 and SLE based on a structured review of 53 studies from 2014 to 2025 and highlight the clinical associations and therapeutic opportunities presented by these autoantibodies. In COVID-19, neutralising anti-IFN-α and/or anti-IFN-ω AAbs were consistently associated with severe disease and impaired antiviral responses, particularly in older male populations. In SLE, anti-IFN-α AAbs were variably detected; neutralising antibodies were associated with reduced interferon gene signatures in some cohorts but inconsistent correlations with disease activity. Therapeutically, anti-IFN-I AAbs in COVID-19 may inform risk stratification and early antiviral strategies, whereas in SLE, IFN-α blockade, including IFN-α kinoid vaccination, demonstrates modulation of IFN signatures but variable clinical benefit. Notably, these findings reveal an immunological paradox: the same neutralising mechanism that impairs antiviral defence in COVID-19 may attenuate chronic IFN-driven inflammation in SLE. Taken together, anti-IFN-I AAbs exert context-dependent effects: pathogenic in acute viral infection yet potentially modulatory in chronic IFN-driven autoimmunity. Prospective longitudinal studies are required to further clarify their translational utility and long-term clinical impact.

Schlagwörter

Stichwörter der Autor:innen

COVID-19autoantibodiesinterferonsystemic lupus erythematous

Autor:innen und Institutionen

  • Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore 308433, Singapore.
  • Health and Social Sciences, Singapore Institute of Technology, Singapore 828608, Singapore.

ORCID-Profile: Xin Rong Lim, Bernard Pui Lam Leung

Zitieren

APA

Lim, X. R., Teo, R. X. W., Par, R. Y. X., & Leung, B. P. L. (2026). Anti-Type I Interferon Autoantibodies in COVID-19 and Systemic Lupus Erythematosus: A Comparative Review. Antibodies, 15(3), 50. https://doi.org/10.3390/antib15030050

Vancouver

Lim XR, Teo RXW, Par RYX, Leung BPL. Anti-Type I Interferon Autoantibodies in COVID-19 and Systemic Lupus Erythematosus: A Comparative Review. Antibodies. 2026;15(3):50. doi:10.3390/antib15030050

BibTeX
@article{Lim2026,
  author = {Lim, Xin Rong and Teo, Ryan Xuan Wei and Par, Rae Yi Xin and Leung, Bernard Pui Lam},
  title = {Anti-Type I Interferon Autoantibodies in COVID-19 and Systemic Lupus Erythematosus: A Comparative Review},
  journal = {Antibodies},
  year = {2026},
  volume = {15},
  number = {3},
  pages = {50},
  doi = {10.3390/antib15030050}
}
Kostenlos starten →